Schedule 13G ownership disclosure
Corcept Therapeutics Inc
Common Stock · CUSIP: 218352102
Event date: 2024-12-31
- Filing-level shares
- 6,822,335
- Percent of class
- 6.3%
- Joseph K. Belanoff
Shares: 6,822,335 · Class: 6.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-021710
- Form type
- SCHEDULE 13G/A
- Filer
- BELANOFF JOSEPH K
- CIK
- CIK 1286199
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership